PCI术后冠状动脉再狭窄机制及防治研究进展

被引：34

作者：

张文利

黄定

机构：

[1] 新疆医科大学第一附属医院心脏中心冠心病科

来源：

中国循证心血管医学杂志 | 2011年 / 02期

关键词：

PCI; 术后再狭窄; 再狭窄率; 药物涂层支架; 支架断裂; 新生内膜; 血管再狭窄; 冠脉介入; 血管平滑肌细胞; 血管内超声; 研究进展;

D O I：

暂无

中图分类号：

R541.4 [冠状动脉（粥样）硬化性心脏病（冠心病）];

学科分类号：

摘要：

<正>经皮冠状动脉内介入治疗术(percutaneous coronary intervention,PCI)是目前医学领域公认的治疗冠心病(coronary heart disease,CHD)的有效手段,但术后冠状动脉(冠脉)再狭窄率高,严重影响了PCI的临床疗效[1]。近些年来,随着药物涂层支架及新

引用

页码：154 / 156

页数：3

共 13 条

[1] 冠状动脉介入术后中西医结合防治再狭窄初探
张光银
张军平
丁彬彬
[J]. 中华中医药杂志, 2010, 25 (08) : 1180 - 1183
[2] 冠心病介入治疗后再狭窄危险因素的Meta分析
吴蕊
杨志明
[J]. 中西医结合心脑血管病杂志, 2009, 7 (04) : 477 - 478
[3] 卡维地洛预防冠状动脉介入治疗后再狭窄的观察
鹿庆华
董兆强
郝林
蒋卫东
王欣
徐冬玲
[J]. 中华心血管病杂志, 2005, (02) : 57 - 57
[4] Substrate-induced phenotypic switches of human smooth muscle cells: an in vitro study of in-stent restenosis activation pathways[J] . Anna L. Guildford,Helen J. S. Stewart,Christopher Morris,Matteo Santin.Journal of the Royal Society Interface . 2011 (58)
[5] Predicting Restenosis of Drug-Eluting Stents Placed in Real-World Clinical Practice: Derivation and Validation of a Risk Model From the EVENT Registry[J] . Joshua M. Stolker,Kevin F. Kennedy,Jason B. Lindsey,Steven P. Marso,Michael J. Pencina,Donald E. Cutlip,Laura Mauri,Neal S. Kleiman,David J. Cohen.Circulation: Cardiovascular Interventions . 2010 (4)
[6] Sirolimus-Eluting Stent Versus Balloon Angioplasty for Sirolimus-Eluting Stent Restenosis: Insights From the j-Cypher Registry[J] . Mitsuru Abe,Takeshi Kimura,Takeshi Morimoto,Takuya Taniguchi,Futoshi Yamanaka,Kazuhiro Nakao,Nobuhito Yagi,Nobuaki Kokubu,Yoichiro Kasahara,Yu Kataoka,Yoritaka Otsuka,Atsushi Kawamura,Shunichi Miyazaki,Koichi Nakao,Kenji Horiuchi,Akira Ito,Hiroshi Hoshizaki,Ren Kawaguchi,Manabu Setoguchi,Tsukasa Inada,Koichi Kishi,Hiroki Sakamoto,Nobuyuki Morioka,Masao Imai,Hiroki S
[7] Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial[J] . Elvin Kedhi,Kaiyum Sheik Joesoef,Eugene McFadden,Jochem Wassing,Carlos van Mieghem,Dick Goedhart,Pieter Cornelis Smits.The Lancet . 2010 (9710)
[8] In-Stent Restenosis in the Drug-Eluting Stent Era
Dangas, George D.
Claessen, Bimmer E.
Caixeta, Adriano
Sanidas, Elias A.
Mintz, Gary S.
Mehran, Roxana
[J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 56 (23) : 1897 - 1907
[9] Long-Term Effectiveness and Safety of Sirolimus Stent Implantation for Coronary In-Stent Restenosis[J] . Francesco Liistro,Massimo Fineschi,Simone Grotti,Paolo Angioli,Arcangelo Carrera,Kenneth Ducci,Tommaso Gori,Giovanni Falsini,Carlo Pierli,Leonardo Bolognese.Journal of the American College of Cardiology . 2010 (7)
[10] Nuclear Receptor Nurr1 Is Expressed In and Is Associated With Human Restenosis and Inhibits Vascular Lesion Formation In Mice Involving Inhibition of Smooth Muscle Cell Proliferation and Inflammation
Bonta, Peter I.
Pols, Thijs W. H.
van Tiel, Claudia M.
Vos, Mariska
Arkenbout, E. Karin
Rohlena, Jakub
Koch, Karel T.
de Maat, Moniek P. M.
Tanck, Michael W. T.
de Winter, Robbert J.
Pannekoek, Hans
Biessen, Erik A. L.
Bot, Ilze
de Vries, Carlie J. M.
[J]. CIRCULATION, 2010, 121 (18) : 2023 - U135

← 1 2 →